0
2021
Cardiac Biomarkers Testing Market

Cardiac Biomarkers Testing Market

by Biomarkers Type (Creatine Kinase (CK-MB), Troponins, Myoglobin, Natriuretic Peptides (BNP and NT-proBNP), Ischemia Modified Albumins, and Other Biomarkers Type), Application (Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome, Atherosclerosis, and Others), and Location of Testing (Point-of-care Testing and Laboratory Testing): Global Opportunity Analysis and Industry Forecast, 2021-2030

Report Code: A04921
Pages: 235
Tables: 109
Charts: 53
  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.

 

The global cardiac biomarkers testing market was valued at $9,766.93 million in 2020, and is projected to reach $28,098.07 million by 2030, registering a CAGR of 10.9% from 2021 to 2030. Cardiac biomarkers are protein molecules that are released into the blood after heart damage or heart-stress. These biomarkers act as a potential tool to detect various cardiovascular diseases (CVD) including cardiac ischemia, myocardial infarction, congestive heart failure, and acute coronary syndrome (ACS). Cardiac biomarker tests allow the doctor to determine the risk of a patient associated with such diseases.

The impact of COVID-19 pandemic is expected to remain positive for the cardiac biomarker testing market. Owing to increase in medical condition such as diabetes heart diseases among others which are more vulnerable to COVID-19. Furthermore, it was estimated that Troponin levels were significantly higher in COVID-19 patients who died or were critically ill due to which cardiac injury biomarkers were elevated in most of the complicated cases of COVID-19.

Cardiac-Biomarkers-Testing-Market-2021-2030

These tests are performed after the patient suffers chest pain. The common cardiac biomarkers that are tested for CVD include troponin, creatine kinase-muscle/brain (CK-MB), B-type natriuretic peptide (BNP), high-sensitivity C-reactive protein (hs-CRP), and others. Cardiac biomarkers that are widely used as an integrated diagnostic approach for cardiovascular diseases (CVDs) include myocardial muscle creatine kinase (CK-MB), troponin I and T, myoglobin, brain natriuretic peptide (BNPs), ischemia modified albumin (IMA), and others. 

The impact of COVID-19 pandemic is expected to remain positive for the cardiac biomarkers testing industry. Owing to increase in the number of COVID-19 patient with preexisting medical condition like cardiovascular diseases and among others. As these patients with existing medical conditions like cardiovascular disease suffering from COVID-19 are more heart attack. Furthermore, it was estimated that troponin levels were significantly higher in COVID-19 patients who died or were critically ill. This has led to increase in the demand of cardiac biomarker testing for the patients suffering from COVID-19. Thus, considering all these factors, the global cardiac biomarkers testing market exhibits positive growth during this pandemic and is expected to gain traction in the upcoming years.

Increase in geriatric population and rise in number of patients suffering from heart attacks & chest pain due to changes in lifestyles are expected to drive the market in the coming years. Furthermore, rise in funding from public and private organizations for research on cardiac biomarkers is expected to boost the market growth in the upcoming years.

However, factors such as limited specificity in some cases and side effects associated with cardiac biomarkers such as skeletal muscle injury are likely to hinder the cardiac biomarkers testing market growth in the upcoming years.

The cardiac biomarkers testing market is segmented on the basis of biomarker type, application, and location of testing. By cardiac biomarker type, the market is divided into creatine kinase (CK-MB), troponins, myoglobin, natriuretic peptides (BNP and NT-proBNP), ischemia modified albumins, and other biomarkers type. By application, the market is classified into myocardial infarction, congestive heart failure, acute coronary syndrome, atherosclerosis, and others. By location of testing, the market is bifurcated into point of care testing and laboratory testing. By region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Cardiac biomarker type segment review

By cardiac biomarker type segment, the troponin segment held the largest share in 2020 and is anticipated to maintain its dominance during the forecast period. This large share is due to increase in the prevalence of acute coronary syndrome and myocardium infarction, rise in the number of congestive heart failure cases across the globe are the key factors to drive the market growth. The creatine kinase is estimated to grow at the highest CAGR 13.0% during the forecast period.

Cardiac Biomarkers Testing Market
By Biomarker Types

Your browser does not support the canvas element.

Troponin segment dominated the market in 2020 and will continue to maintain the lead over the forecast period.

Get more information on this report : Request Sample Pages

Application segment review

By application, the market is segmented into myocardial infarction, congestive heart failure, acute coronary syndrome, atherosclerosis, and others. The myocardial infarction accounted for the larger share in 2020, whereas, congestive Heart Failure segment is the faster growing segment with a CAGR of 12.2% owing to increase in cardiovascular disease and increased demand for biomarker tests for early detection of heart failure are key factors anticipated to boost the growth of the global cardiac biomarkers testing market in future.

Cardiac Biomarkers Testing Market
By Application

Your browser does not support the canvas element.

Myocardial infarction segment held the dominant position in 2020 and would continue to maintain the lead over the forecast period.

Get more information on this report : Request Sample Pages

Location of testing segment review

On the basis of location of testing, the laboratory testing segment held the largest share in 2020 and is anticipated to maintain its dominance during the forecast period, owing to the reform in healthcare infrastructure, increase in healthcare spending, rise in disposable incomes, and government initiatives for preventing heart attack are expected to drive the cardiac biomarkers testing market in the Asia-Pacific region. Thus, the increase in cardiovascular diseases (CVDs) around the globe, has augmented the demand for cardiac biomarkers testing for lowering the burden of heart attack and other CVDs.

Cardiac Biomarkers Testing Market
By Location Of Testing

Your browser does not support the canvas element.

Laboratory testing segement held a dominant position in 2020 and continue to maintain lead in the forecast year

Get more information on this report : Request Sample Pages

Region segment review

By region, North America accounted for the largest share in 2020, and is anticipated to maintain its dominance from 2020 to 2030, due to high expenditure on R&D, presence of major players & their product availability, and well-established healthcare infrastructure in the region. However, Asia-Pacific is expected to register the highest CAGR of 12.5% during the forecast period, as Governments of Asian countries are investing in the development of healthcare infrastructure.

Cardiac Biomarkers Testing Market
By Region

2030
North America 
Europe
Asia-Pacific
LAMEA

Asia-Pacific region would exhibit the highest CAGR of 12.50% during 2020-2028.

Get more information on this report : Request Sample Pages

Some of the key players operating in the global cardiac biomarkers testing market include Abbott Laboratories, Becton, Dickinson and Company, bioMerieux, Inc., Bio-Rad Laboratories, Inc., Danaher Corporation, F. Hoffmann-La Roche Ltd., PerkinElmer Inc., Siemens AG, Thermo Fisher Scientific, Inc., and Tosoh Corporation. 

Key Benefits For Stakeholders

  • This report entails a detailed quantitative analysis along with the current global cardiac biomarkers testing market trends from 2020 to 2030 to identify the prevailing opportunities along with the strategic assessment.
  • The cardiac biomarkers testing market forecast is studied from 2020 to 2030.
  • The market size and estimations are based on a comprehensive analysis of key developments in the cardiac biomarkers testing industry.
  • A qualitative analysis based on innovative products facilitates strategic business planning.
  • The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the cardiac biomarkers testing market.

Cardiac Biomarkers Testing Market Report Highlights

Aspects Details
By BIOMARKERS TYPE
  • Creatine kinase (CK-MB)
  • Troponins
  • Myoglobin
  • Natriuretic peptides (BNP and NT-proBNP)
  • Ischemia modified albumin (IMA)
  • Other biomarkers type
By Application
  • Myocardial Infarction
  • Congestive Heart Failure
  • Acute coronary syndrome (ACS)
  • Atherosclerosis
  • Other applications
By Location Of Testing
  • Point of Care Testing
  • Laboratory Testing
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (Uk, France, Germany, Rest of Europe)
  • Asia-Pacific  (China, India, Australia, Japan, Rest of Asia-Pacific)
  • LAMEA  (Latin America, Middle East, Africa)
Key Market Players TOSOH CORPORATION, THERMO FISHER SCIENTIFIC, INC., ABBOTT LABORATORIES, DANAHER CORPORATION, BIOMERIEUX, INC., F. HOFFMANN-LA ROCHE LTD., BECTON, DICKINSON AND COMPANY, BIO-RAD LABORATORIES, INC., PERKINELMER INC., SIEMENS AG
 

Loading Table Of Content...


 
 

In accordance to several interviews conducted, the cardiac biomarkers testing market is expected to witness a steady growth in the future. Owing to development of novel and advanced cardiac biomarkers such as, troponin and myoglobin that would help in early detection of cardiac disorders is a major factor that boosts the market growth for cardiac biomarkers. This has increased the adoption of cardiac biomarkers across the world. Decrease in the cost of medical devices and increase in awareness for early diagnosis & prognosis of cardiac diseases have offered lucrative opportunities for the growth of the cardiac biomarkers market. Moreover, cardiac biomarkers find their application in list of chronic to mid cardiovascular conditions, which fuel their adoption across the globe, thereby propelling the market growth. The adoption of cardiac biomarkers has increased considerably, owing to their easy operational features and increase in awareness for early disease diagnosis is expected to boost the market growth in the near future.

Purchase Options

Call or Email Us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com
 
Published Date :
Jul 2021
Author(s) : Kishor S, Vikita T , Onkar S
FREQUENTLY ASKED QUESTIONS?

A. The total market value of Cardiac Biomarkers Testing Market was $9,766.93 million in 2020

A. The forecast period in the report is from 2021 to 2030

A. The CAGR of Cardiac Biomarkers Testing Market during the forecast period is 10.9%.

A. Yes, Cardiac Biomarkers Testing Market companies are profiled in the report

A. The top companies that hold the market share in Cardiac Biomarkers Testing Market are are Abbott Laboratories, Becton, Dickinson and Company, BioMerieux, Inc., Bio-Rad Laboratories, Inc., and Danaher Corporation.

A. yes, there is value chain analysis provided in the Cardiac Biomarkers Testing Market report

A. The key trends in the Cardiac Biomarkers Testing Market are due to rise of prevalence of cardiac diseases that widely remain undiagnosed and rise in geriatric population.

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Request Sample
Related Tags

Purchase Full Report of
Cardiac Biomarkers Testing Market

Start reading instantly.
This Report and over 71,225+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,712  $3,341
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
    (Jul 2022)
  • Data Pack
  • $4,125  $3,713
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Jul 2022)
  • Single User
  • $5,769  $4,904
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Jul 2022)
  • Five Users
  • $6,929  $5,890
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Jul 2022)
  • Enterprise
    License/PDF

  • $10,663  $8,530
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Jul 2022)
  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

Related Reports
*Terms and Conditions Apply
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of the scope of the report to exactly meet your needs

Targeted Market View

Targeted market view to provide pertinent information and save time for readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of the scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save the time of readers